Loading
A phase 2 trial of Lunresertib run by Canadian Cancer Trials Group, completed.
RP-6306 in Patients With Advanced Cancer is a phase 2 interventional study registered as NCT05605509 by Canadian Cancer Trials Group, with 28 participants enrolled, started 2023-05-24. Conditions recorded: Advanced Cancer. Interventions recorded: RP-6306, Gemcitabine, FOLFIRI Protocol, Trastuzumab and RP-3500.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Debiopharm and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/